These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

835 related articles for article (PubMed ID: 25128049)

  • 1. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes.
    Ly TT; Brnabic AJ; Eggleston A; Kolivos A; McBride ME; Schrover R; Jones TW
    Value Health; 2014 Jul; 17(5):561-9. PubMed ID: 25128049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial.
    Ly TT; Nicholas JA; Retterath A; Lim EM; Davis EA; Jones TW
    JAMA; 2013 Sep; 310(12):1240-7. PubMed ID: 24065010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark.
    Roze S; de Portu S; Smith-Palmer J; Delbaere A; Valentine W; Ridderstråle M
    Diabetes Res Clin Pract; 2017 Jun; 128():6-14. PubMed ID: 28432898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy.
    Nicolucci A; Rossi MC; D'Ostilio D; Delbaere A; de Portu S; Roze S
    Nutr Metab Cardiovasc Dis; 2018 Jul; 28(7):707-715. PubMed ID: 29753586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes.
    Roze S; Saunders R; Brandt AS; de Portu S; Papo NL; Jendle J
    Diabet Med; 2015 May; 32(5):618-26. PubMed ID: 25483869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France.
    Roze S; Smith-Palmer J; Valentine W; Payet V; de Portu S; Papo N; Cucherat M; Hanaire H
    Diabetes Technol Ther; 2016 Feb; 18(2):75-84. PubMed ID: 26646072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Efficacy and Safety of Sensor Augmented Insulin Pump Therapy with Low-Glucose Suspend Feature in Patients with Type 1 Diabetes.
    Gómez AM; Marín Carrillo LF; Muñoz Velandia OM; Rondón Sepúlveda MA; Arévalo Correa CM; Mora Garzón E; Cuervo Diaz MC; Henao Carrillo DC
    Diabetes Technol Ther; 2017 Feb; 19(2):109-114. PubMed ID: 28001445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey.
    Roze S; Smith-Palmer J; de Portu S; Özdemir Saltik AZ; Akgül T; Deyneli O
    Diabetes Technol Ther; 2019 Dec; 21(12):727-735. PubMed ID: 31509715
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
    Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
    Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of performing morning versus afternoon exercise on glycemic control and hypoglycemia frequency in type 1 diabetes patients on sensor-augmented insulin pump therapy.
    Gomez AM; Gomez C; Aschner P; Veloza A; Muñoz O; Rubio C; Vallejo S
    J Diabetes Sci Technol; 2015 May; 9(3):619-24. PubMed ID: 25555390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study.
    Garg S; Brazg RL; Bailey TS; Buckingham BA; Slover RH; Klonoff DC; Shin J; Welsh JB; Kaufman FR
    Diabetes Technol Ther; 2012 Mar; 14(3):205-9. PubMed ID: 22316089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain.
    Conget I; Martín-Vaquero P; Roze S; Elías I; Pineda C; Álvarez M; Delbaere A; Ampudia-Blasco FJ
    Endocrinol Diabetes Nutr (Engl Ed); 2018; 65(7):380-386. PubMed ID: 29789227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of predicted low suspend pump treatment on improving glycaemic control and quality of sleep in children with type 1 diabetes and their caregivers: the QUEST randomized crossover study.
    Schierloh U; Aguayo GA; Fichelle M; De Melo Dias C; Celebic A; Vaillant M; Barnard K; Cohen O; de Beaufort C
    Trials; 2018 Dec; 19(1):665. PubMed ID: 30509293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sensor-augmented pump therapy (SAPT) with predictive low-glucose management in patients diagnosed with type 1 diabetes mellitus previously treated with SAPT and low glucose suspend.
    Gómez AM; Henao DC; Imitola A; Muñoz OM; Sepúlveda MAR; Kattah L; Guerrero JS; Morros E; Llano JP; Jaramillo MG; León-Vargas F
    Endocrinol Diabetes Nutr (Engl Ed); 2018 Oct; 65(8):451-457. PubMed ID: 29914817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Numerical and clinical precision of continuous glucose monitoring in Colombian patients treated with insulin infusion pump with automated suspension in hypoglycemia.
    Gómez AM; Marín Sánchez A; Muñoz OM; Colón Peña CA
    Endocrinol Nutr; 2015 Dec; 62(10):485-92. PubMed ID: 26531841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in older adults: A retrospective study in Bogota, Colombia.
    Morros-González E; Gómez AM; Henao Carrillo DC; Ursida V; Serrano S; Rondón Sepúlveda MA; Muñoz Velandia OM
    Diabetes Metab Syndr; 2021; 15(3):649-653. PubMed ID: 33813236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
    Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
    Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.